CONCENTRAID
LOE ApproachingNDANASALSOLUTION
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONCENTRAID is a nasal solution small-molecule NDA approved in 1990 by Ferring Pharmaceuticals. The specific indication and mechanism of action are not publicly detailed in available data, limiting assessment of therapeutic positioning. This product represents a legacy nasal formulation in an era of advanced delivery technologies.
LOE Approaching
Product is in decline phase with low commercial activity; team likely focused on lifecycle management and generic transition rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONCENTRAID offers minimal career growth opportunity; current openings are zero, and the product is in lifecycle decline. Roles are likely specialized in retention and managed care navigation rather than commercial expansion or innovation.
Brand ManagerProduct Manager
Worked on CONCENTRAID at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.